Blazar B R, Widmer M B, Soderling C C, Gillis S, Vallera D A
Department of Pediatrics, University of Minnesota Hospitals, Minneapolis 55455.
Blood. 1988 Oct;72(4):1148-54.
In vivo administration of murine recombinant granulocyte/macrophage colony stimulating factor (rGM-CSF) was evaluated for effects on survival and engraftment in an allogeneic murine bone marrow transplantation (BMT) model involving T-cell depletion of donor marrow. The model provides a high incidence of graft failure/rejection. Recipients of continuous subcutaneous infusions of rGM-CSF had a significant survival advantage when compared with untreated controls. However, a significantly lower incidence of donor cell engraftment was noted. Hematological parameters were not substantially affected. When rGM-CSF was administered intraperitoneally (IP), twice daily injections closely approximated the effects of continuous infusion on survival. Single IP injections were without significant effects on survival or engraftment. These results demonstrate that prolonged frequent in vivo exposure to rGM-CSF can significantly improve survival but significantly decreases donor cell repopulation in recipients of T-cell-depleted histoincompatible marrow grafts.
在一个供体骨髓进行T细胞清除的异基因小鼠骨髓移植（BMT）模型中，评估了小鼠重组粒细胞/巨噬细胞集落刺激因子（rGM-CSF）的体内给药对生存和植入的影响。该模型移植失败/排斥发生率很高。与未治疗的对照组相比，持续皮下输注rGM-CSF的受体具有显著的生存优势。然而，观察到供体细胞植入的发生率显著降低。血液学参数未受到实质性影响。当腹腔内（IP）给予rGM-CSF时，每日两次注射对生存的影响与持续输注相近。单次IP注射对生存或植入没有显著影响。这些结果表明，在T细胞清除的组织不相容骨髓移植受体中，长时间频繁体内暴露于rGM-CSF可显著提高生存率，但显著降低供体细胞的再增殖。
